Staff directory

Search for a surname in the box below and then click "Search" to search for Staff. 

If you want to get in touch but you don’t know who to contact, fill in our enquiry form and one of our advisers will get back to you as soon as possible.
7 results

Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo

Journal Article
Mathur, S., Turnbull, A., Akaev, I., Stevens, C., Agrawal, N., Chopra, M., & Mincher, D. (in press)
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo. International Journal of Peptide Research and Therapeutics, https://doi.org/10.1007/s10989-019-09994-1
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Ov...

Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections

Presentation / Conference
Oluwadare, E., Rehan, A., Ding, Y., Turnbull, A., Malone, E., Mincher, D., & Proudfoot, L. (2016, September)
Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections. Poster presented at Molecular & Cellular Biology of Helminth Parasites X, Hydra, Greece
Anthelmintic resistance and the shortage of new drugs represent an urgent need for the development of novel anti-parasite drugs with effective delivery to the target site. Red...

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Journal Article
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. (2016)
Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer. European Journal of Cancer, 61, S142. https://doi.org/10.1016/s0959-8049%2816%2961501-0
Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biom...

Targeting an MMP-9-activated prodrug to multiple myeloma diseased bone marrow: a proof of principle in the 5T33MM mouse model.

Journal Article
Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B. & Vanderkerken, K. (2005)
Targeting an MMP-9-activated prodrug to multiple myeloma diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia. 19, 1628 -1633. doi:10.1038/sj.leu.2403866. ISSN 0887-6924
Multiple myeloma (MM) is an incurable B-cell cancer characterised by the monoclonal proliferation of tumour cells in the bone marrow (BM). It has been described that matrix me...

Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents.

Journal Article
Dias, N., Goossens, J., Baldeyrou, B., Lansiaux, A., Colson, P., Di Salvo, A., …Bailly, C. (2005)
Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. Bioconjugate Chemistry. 16, 949 - 958. doi:10.1021/bc050065x. ISSN 1043-1802
We report the synthesis of an original series of oxoazabenzo[de]anthracenes conjugated to an amino acid: Ala, Phe, Pro, Lys, or Gly (4a-e, respectively). The compounds, derive...

Anthracene derivatives as anti-cancer agents.

Patent
Mincher, D. & Turnbull, A. (2004)
Anthracene derivatives as anti-cancer agents.
The present invention relates to compounds which are based on an anthraquinone nucleus for use in medicine, particularly as anti-cancer agents which exert their effects throug...

Stereospecific synthesis of chiral caprolactone monomers from D-glucose.

Journal Article
Defossemont, G. & Mincher, D. (2003)
Stereospecific synthesis of chiral caprolactone monomers from D-glucose. Carbohydrate Research. 338, 563-565. doi:10.1016/S0008-6215(02)00490-1. ISSN 0008-6215
The synthesis and characterisation of a novel chiral bicyclic oxacaprolactone is reported. The choice of diisopropylidene- -glucose as a starting material allowed selective in...
17 results

An investigation of successful surf therapy programmes and their key mechanisms of change

2018 - date
James Marshall | Director of Studies: Prof Russell Martindale | Second Supervisor: Mr Brendon Ferrier

Synthesis and flourescence properties of a novel legumain substrate probe

2018 - date
Deepthi Ravula | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Disaster and everyday life: Dynamics of vulnerability and resilience among Tibetan refugees in the 2015 Nepal earthquake

2018 - date
Kyle Schwartz | Director of Studies: Dr Kiril Sharapov | Second Supervisor: Prof Richard Whitecross

Design and development of novel targeted anticancer drugs.

2018 - date
Ewoma Akpughe | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and cytotoxicity of bifunctional anticancer agents targeted to mitochondria DNA processing enzymes

2018 - date
Mohamad Kamel | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and biological evaluation of novel targeted anthelmintic agents

2015 - 2020
Aiman Rehan | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design, synthesis and evaluation of novel and clinically used anti-cancer agents targeted intracellularly

2014 - date
The majority of clinically used anticancer drugs suffer from poor selectivity for tumour cells ...
Omar Mohammed | Director of Studies: Dr David Mincher | Second Supervisor: Agnes Turnbull

Design and evaluation of new theranostic molecular probes and prodrugs in cancer

2013 - 2017
Sunil Mathur | Director of Studies: Dr David Mincher | Second Supervisor: Dr Craig Stevens

The development of a caenorhabtitis elegans model for the assessment of toxicity: application in the treatment of parasitic worm infections

2013 - 2017
Eyitayo Oluwadare | Director of Studies: Dr Lorna Proudfoot | Second Supervisor: Dr Eva Malone

Design, synthesis and evaluation of novel vascular disrupting prodrugs targeted to legumain in the tumour microenvironment

2012 - 2015
Claire Finlay | Director of Studies: Dr David Mincher | Second Supervisor: Dr Craig Stevens

Date


Date